Pivitko 150mg

Pivitko 150mg is a prescription medication used to treat certain types of cancer, including breast cancer, lung cancer, and other types of solid tumors. It is a PI3K inhibitor that works by inhibiting the growth of cancer cells and reducing the production of new blood vessels that feed the tumor.

Composition:

• Pivitko 150mg: Alpelisib (150mg)

Mechanism of Action:

Alpelisib, the active ingredient in Pivitko, is a PI3K inhibitor that works by:

1. Inhibiting the growth of cancer cells by blocking the action of specific enzymes that promote cell growth and division.
2. Reducing the production of new blood vessels that feed the tumor, which helps to reduce its growth and spread.
3. Inhibiting the activity of various signaling pathways that contribute to cancer cell growth and survival.

Indications:

Pivitko is approved for the treatment of:

1. Advanced or metastatic breast cancer in combination with fulvestrant (Faslodex) in patients who have progressed after previous treatment.
2. Advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have progressed after previous treatment and have tumors with an activating PI3K mutation.

Dosage:

The recommended dosage of Pivitko is:

• 150mg orally once daily, taken at the same time every day.
• The recommended duration of treatment is until disease progression or unacceptable toxicity.

Side Effects:

Common side effects of Pivitko include:

1. Nausea
2. Fatigue
3. Diarrhea
4. Abdominal pain
5. Headache
6. Skin rash
7. Hair loss
8. Muscle pain
9. Increased risk of bleeding or bruising
10. Increased risk of liver enzyme elevation

Recommendation:

Pivitko is recommended for patients who have been diagnosed with advanced or metastatic breast cancer or NSCLC and have not responded to other treatments or have disease that has progressed after surgery and radiation therapy.

Important Note:

• Patients taking Pivitko should be closely monitored for signs of bleeding or bruising due to the risk of thrombocytopenia.
• Patients taking Pivitko should avoid taking medications that may increase the risk of bleeding or bruising.
• Pregnant or breastfeeding women should not use Pivitko, as it may harm the fetus or infant.
• Regular follow-up appointments with your healthcare provider are necessary to monitor the effectiveness of Pivitko and to detect any potential side effects or complications.

Special Precautions:

• Patients with a history of kidney disease should be closely monitored for signs of worsening kidney function while taking Pivitko.
• Patients taking Pivitko should avoid taking medications that may interact with it, such as anticoagulants or medications that can increase blood pressure.
• Patients with a history of heart disease or high blood pressure should be closely monitored while taking Pivitko.

Contraindications:

• Patients with severe liver disease or severe kidney disease should not use Pivitko.
• Patients who are allergic to alpelisib or any other component of Pivitko should not use it.
• Patients who are pregnant or breastfeeding should not use Pivitko.